Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
Jacob Eifer MollerThomas EngstrømLisette O JensenHans EiskjærNorman MangnerAmin PolzinP Christian SchulzeCarsten SkurkPeter NordbeckPeter ClemmensenVasileios PanoulasSebastian ZimmerAndreas SchäferNikos WernerMartin FrydlandLene HolmvangJesper KjærgaardRikke SørensenJacob LønborgMatias G LindholmNanna L J UdesenAnders JunkerHenrik SchmidtChristian J TerkelsenSteffen ChristensenEvald H ChristiansenAxel LinkeFelix J WoitekRalf WestenfeldSven Möbius-WinklerKristian WachtellHanne B RavnJens F LassenSøren BoesgaardOke GerkeChristian Hassagernull nullPublished in: The New England journal of medicine (2024)
The routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The incidence of a composite of adverse events was higher with the use of the microaxial flow pump. (Funded by the Danish Heart Foundation and Abiomed; DanGer Shock ClinicalTrials.gov number, NCT01633502.).